Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H40N8O4 |
Molecular Weight | 504.6265 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO
InChI
InChIKey=IZEKFCXSFNUWAM-UHFFFAOYSA-N
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
DescriptionSources: http://www.drugbank.ca/drugs/DB00975Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/012836s057lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00975
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/012836s057lbl.pdf
Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis. Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation. Used for as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
CNS Activity
Sources: https://web.archive.org/web/20170215181448/http://files.boehringer.com.au/files/PI/Persantin%20100%20PI.pdf
Curator's Comment:: Dipyridamole does not cross the blood brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17636949 |
144.8 nM [IC50] | ||
Target ID: CHEMBL4409 Sources: http://www.drugbank.ca/drugs/DB00975 |
1.2 µM [IC50] | ||
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8254606 |
0.52 µM [IC50] | ||
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9873613 |
0.5 µM [IC50] | ||
Target ID: CHEMBL1910 Sources: http://www.drugbank.ca/drugs/DB00975 |
45.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Persantine Approved UsePersantine (dipyridamole USP) tablets are indicated as an adjunct to coumarin anticoagulants in the prevention
of postoperative thromboembolic complications of cardiac valve replacement. Launch Date-2.54793597E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1881 ng/mL |
200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
475 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2781 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2825745 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15030 ng × h/mL |
200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2492 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15779 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2825745 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.74 h |
200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.3 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPYRIDAMOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
DIPYRIDAMOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: Page: p.75 |
healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: Page: p.75 |
Disc. AE: Loss of consciousness, Respiratory distress... AEs leading to discontinuation/dose reduction: Loss of consciousness Sources: Page: p.75Respiratory distress Apnea Coma |
8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Disc. AE: Tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Tachycardia Sources: Page: e15Hypotension Multi-organ failure Delirium Anuria Renal failure |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Disc. AE: Headache, Diarrhoea... AEs leading to discontinuation/dose reduction: Headache (9.1%) Sources: Page: p.1786Diarrhoea (3.5%) Nausea (1.5%) Vomiting (2%) Dyspepsia (1.5%) |
5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.62 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Angina pectoris Age Group: 62 Sex: F Population Size: 1 Sources: Page: p.62 |
Disc. AE: Myocardial infarction... AEs leading to discontinuation/dose reduction: Myocardial infarction Sources: Page: p.62 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Apnea | Disc. AE | 1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: Page: p.75 |
healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: Page: p.75 |
Coma | Disc. AE | 1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: Page: p.75 |
healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: Page: p.75 |
Loss of consciousness | Disc. AE | 1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: Page: p.75 |
healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: Page: p.75 |
Respiratory distress | Disc. AE | 1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: Page: p.75 |
healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: Page: p.75 |
Anuria | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Delirium | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Hypotension | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Multi-organ failure | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Renal failure | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Tachycardia | Disc. AE | 8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: Page: e15 |
healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: Page: e15 |
Dyspepsia | 1.5% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Nausea | 1.5% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Vomiting | 2% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Diarrhoea | 3.5% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Headache | 9.1% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1786 |
unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: Page: p.1786 |
Myocardial infarction | Disc. AE | 5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: Page: p.62 |
unhealthy, 62 n = 1 Health Status: unhealthy Condition: Angina pectoris Age Group: 62 Sex: F Population Size: 1 Sources: Page: p.62 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [Activation 27.71665 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
yes [Activation 1.2589 uM] | ||||
yes [Activation 10 uM] | ||||
yes [Activation 10 uM] | ||||
yes [Activation 5.0119 uM] | ||||
yes [IC50 2.6 uM] | ||||
yes [IC50 26 uM] | ||||
yes [IC50 30 uM] | ||||
yes [IC50 4 uM] | ||||
yes [IC50 4.8 uM] | ||||
yes [IC50 40 uM] | ||||
yes [IC50 74 uM] | ||||
yes [IC50 8.3 uM] | ||||
yes [IC50 81 uM] | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Page: 7.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A1 adenosine receptor activation increases adipocyte leptin secretion. | 2000 Apr |
|
Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. | 2000 Jan 4 |
|
Echo-dipyridamole stress test evaluation of isosorbide-5-mononitrate efficacy and tolerance in patients with coronary heart disease: interplay with sympathetic activity. | 2000 Jul |
|
Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. | 2000 May 27 |
|
Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation. | 2001 |
|
Metabolic fate of extracellular NAD in human skin fibroblasts. | 2001 |
|
Antithrombotic drugs for secondary stroke prophylaxis. | 2001 Apr |
|
Repeated thromboembolic and bleeding events after mechanical aortic valve replacement. | 2001 Apr |
|
Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. | 2001 Apr |
|
Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. | 2001 Apr |
|
Prognostic value of pharmacologic stress echocardiography in patients with left bundle branch block. | 2001 Apr 1 |
|
Adenosine permeation of a dynamic in vitro blood-brain barrier inhibited by dipyridamole. | 2001 Apr 13 |
|
Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei. | 2001 Apr 13 |
|
Antiplatelet agents in tissue factor-induced blood coagulation. | 2001 Apr 15 |
|
Assessment of the effect of revascularization early after CABG using ECG-gated perfusion single-photon emission tomography. | 2001 Feb |
|
Preoperative dipyridamole-thallium scanning, selective coronary revascularization and long-term survival in patients with critical lower limb ischemia. | 2001 Feb |
|
The use of L-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. | 2001 Feb |
|
Newer antiplatelet therapies in stroke prevention. | 2001 Feb |
|
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. | 2001 Feb |
|
Antithrombotic therapy in valvular heart disease. | 2001 Feb |
|
Quantification of myocardial perfusion in human subjects using 82Rb and wavelet-based noise reduction. | 2001 Feb |
|
Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. | 2001 Feb |
|
Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium. | 2001 Feb |
|
Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin) coating on its lumenal surface. | 2001 Feb |
|
Aggrenox and stress testing. | 2001 Feb 27 |
|
Effect of dipyridamole on ischemia and reperfusion injury of canine liver. | 2001 Feb-Mar |
|
Role of relative myocardial perfusion reserve for evaluating stenosis severity in patients with single-vessel coronary artery disease using. | 2001 Jan |
|
Congenital heart disease: current indications for antithrombotic therapy in pediatric patients. | 2001 Jan |
|
The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. | 2001 Jan |
|
Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site. | 2001 Jan 10 |
|
Saphenous vein endothelial cell viability: a comparative study of endoscopic and open saphenectomy for coronary artery bypass grafting. | 2001 Jan-Mar |
|
Action of dipyridamole and warfarin on growth of human endothelial cells cultured in serum-free media. | 2001 Mar |
|
[Reporting echocardiography exams with the G8-Cardio ANMCO software]. | 2001 Mar |
|
Progressive intracranial vascular disease with strokes and seizures in a boy with progeria. | 2001 Mar |
|
Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. | 2001 Mar |
|
Use of dobutamine stress echocardiography in determination of myocardial viability. | 2001 Mar |
|
Myocardial flow reserve parametric map, assessed by first-pass MRI compartmental analysis at the chronic stage of infarction. | 2001 Mar |
|
Operator independent left ventricular function monitoring during pharmacological stress echo with the new peak transcutaneous acceleration signal. | 2001 Mar |
|
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats. | 2001 Mar |
|
Activation of glutamate uptake by guanosine in primary astrocyte cultures. | 2001 Mar 26 |
|
Preliminary clinical results of photon energy recovery in simultaneous rest Tl-201/stress Tc-99m sestamibi myocardial SPECT. | 2001 Mar-Apr |
|
Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. | 2001 Mar-Apr |
|
Dipyridamole myocardial SPECT with low heart rate response indicates cardiac autonomic dysfunction in patients with diabetes. | 2001 Mar-Apr |
|
Effect of power Doppler and digital subtraction techniques on the comparison of myocardial contrast echocardiography with SPECT. | 2001 May |
Sample Use Guides
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16103157
Mengovirus plaque formation in HeLa or L cells was inhibited nearly 100% by the presence of 80 uM dipyridamole.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
||
|
NDF-RT |
N0000008832
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
||
|
NDF-RT |
N0000175578
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
||
|
NDF-RT |
N0000008832
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
||
|
WHO-ATC |
B01AC07
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
||
|
WHO-VATC |
QB01AC07
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL932
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
1220506
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | USP-RS | ||
|
C445
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
DB00975
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
4807
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
200-374-7
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
64ALC7F90C
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
D004176
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
924
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
SUB07229MIG
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
M4658
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | Merck Index | ||
|
3521
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | RxNorm | ||
|
1545
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
3108
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
58-32-2
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
DIPYRIDAMOLE
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
Dipyridamole
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY | |||
|
58-32-2
Created by
admin on Fri Jun 25 20:54:52 UTC 2021 , Edited by admin on Fri Jun 25 20:54:52 UTC 2021
|
PRIMARY |
ACTIVE MOIETY